

BLOOD

Textbook of Hematology

James H. Jandl

BLOOD

Textbook of Hematology



James H. Jandl, M.D.

George Richards Minot Professor of Medicine
Harvard Medical School

Physician
Beth Israel Hospital

Senior Consultant in Medicine
Brigham and Women's Hospital
Boston



Little, Brown and Company
Boston/Toronto

Copyright © 1987 by James H. Jandl

First Edition

All rights reserved. No part of this book may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher, except by a reviewer who may quote brief passages in a review.

Library of Congress Catalog Card No.
87-80636

ISBN 0-316-45729-9

Printed in the United States of America

MV

James H. Jandl, M.D.

George Richards Minot Professor of Medicine

Harvard Medical School

Physician

Beth Israel Hospital

Senior Consultant in Medicine

Bingham and Women's Hospital

Boston

Little, Brown and Company

Boston/Toronto

Preface

It was my good fortune to enter the trade of hematology before its partition into several independent sovereignties. In the tradition of my mentors, Dr. William B. Castle and Dr. Maxwell Finland, to whom this work is dedicated, I have treated the clinical and molecular aspects of all blood disorders as being inseparable. The origins, manifestations, and treatment of hematologic diseases are described here in language common to both clinical and basic science. It follows that this textbook should be understandable and useful to students, hematologists, generalists, and biologists of all persuasions. In recognition that each of the myriad domains now encompassed by hematology differs in scope, depth, and public significance, the individual chapters are tailored to fit the topic. While following the logical organizational train from definition to treatment, the author has refrained from forcing subject matter into procrustean order or boilerplate format.

Solo authorship of a book of this scope is made possible in some part through electronic facilitation. In greater part, in my case, the monumental task of putting this book together can be attributed mainly to the talents and editorial proficiency of Ronald Rouse.

The single author has a special advantage over conglomerates of writers: the full control over contents promotes efficiency, eliminates redundancy, and provides the reader with uniformity of style. Some deliberate redundancy is built in for reinforcing complex topics. The style used here is declarative; its clarity must be judged by the reader.

The author has leaned heavily upon visual aids borrowed selectively from the vast treasury of medical and biological literature. The majority of morphologic exhibits, and all uncredited photomicrographs, are the work of Carola T. von Kapff, whose gift for selecting and identifying representative fields in blood smears and marrow biopsies is unrivaled.

The author owes a unique debt of gratitude to Dr. John W. Harris and his associates, who meticulously scrutinized each chapter as it was processed. The vigilant editorial labors of John Harris, and those of Jane MacNeil of Little, Brown, have helped to eliminate gaffes, repair omissions, and sharpen the accuracy of this presentation.

The aim of this work is to provide a textbook of clinical hematology proportioned to suit the practicing physician's needs in understanding hematologic disorders and their management. It is intended to be both comprehensive and comprehensible. Its goal is to cover but not smother the wants of all—students, physicians, technologists, and concerned laity—who wish to, or must, learn more about blood.

J. H. J.

Contents

Preface xxvii

1. Blood and Bloodforming Tissues 1

STEM CELLS 1

The Stem Cell Hierarchy 1

Differentiation and the Microenvironment 2

Colony Proliferation Is Stimulated by Both Specific and Nonspecific CSFs 2

SELF-RENEWAL AND THE PROLIFERATIVE STEADY STATE 3

CYTOKINETICS AND MATURATION-DIVISION OF HEMATOPOIETIC CELLS 5

THE GENERATIVE CYCLE 5

CYTOGENETICS 9

CHROMOSOME BAND NOMENCLATURE AND DESIGNATION OF STRUCTURAL

ABNORMALITIES 10

X CHROMOSOME INACTIVATION 12

Stem Cell Growth and Clonal Diseases 13

ONTOGENY OF HEMATOPOIESIS 14

MEDULLARY HEMATOPOIESIS 16

BONE MARROW SIZE AND COMPOSITION 17

CELLULARITY OF BONE MARROW 20

Marrow Imaging 21

BONE MARROW ASPIRATION 22

NEDLE BIOPSY OF BONE MARROW 25

PREPARATION OF BONE MARROW SPECIMENS 26

ESTIMATION OF CELLULARITY 27

M : E Ratio 27

Marrow Differential Count 27

Normal Numerical Values for Blood 28

THE COMPLETE BLOOD COUNT (CBC) 29

Morphologic Examination of Blood Cells 33

Special Histochemical Stains 33

BLOOD VOLUME AND FLOW 36

Blood Viscosity and Other Determinants of Intravascular Blood Flow 37

Rouleaux 38

The Importance of Axial Streaming 40

BLOOD VISCOSITY AND O₂ TRANSPORT 41

2. Physiology of Red Cells 49

The Erythron 49

ERYTHROBLAST MATURATION AND DIFFERENTIATION 49

Balanced and Unbalanced Growth 51

REGULATION OF ERYTHROPOIESIS 51

ERYTHROPOIETIN 52

STRUCTURE AND SHAPE OF RED CELLS 54

THE CYTOSKELETON 54

Membrane Lipids 56

REGULATION OF RED CELL VOLUME 58

MEMBRANE TRANSPORT OF IONS 59

Red Cell Glycolysis 59

MECHANISMS OF RESPONSE TO OXIDANT STRESS 61

METHEMOGLOBIN REDUCTION 62

GLUTATHIONE METABOLISM 63

Adenosine Triphosphate (ATP) 64

ATP, ATPase, and the Sodium Pump 64

ATP, ATPase, and the Calcium Pump 65

THE ANION CHANNEL 66

Receptor-Mediated Endocytosis 67

TRANSFERRIN AND THE TRANSFERRIN RECEPTOR 67

HEMOGLOBIN AND O₂ TRANSPORT 72

O₂ Dissociation Curve 72

	THE STRUCTURE OF NORMAL HEMOGLOBINS	72
	O ₂ BINDING AND SUBUNIT COOPERATIVITY	73
	Allosteric Regulation of Hemoglobin by 2,3-DPG and Other Organic Phosphates	75
	HEMOGLOBIN BIOSYNTHESIS	76
	GLOBIN GENES	76
	EXONS AND INTRONS	77
	The Genetic Code	77
	TRANSCRIPTION OF DNA	78
	METHODS OF DNA ANALYSIS AND MAPPING OF GLOBIN GENES	79
	Restriction Endonucleases	80
	Application of Recombinant DNA Technology	81
	End Product Inhibition by α Chains	82
	HEME SYNTHESIS	83
	THE REGULATORY ROLES OF ALA AND HEME	84
	THE PORPHYRIAS	85
	CONGENITAL ERYTHROPOIETIC PORPHYRIA	85
	PORPHYRIA CUTANEA TARDA	85
	Hepatoerythropoietic Porphyria	85
	PROTOPORPHYRIA	85
	ACUTE INTERMITTENT PORPHYRIA	86
	VARIEGATE PORPHYRIA (SOUTH AFRICAN GENETIC PORPHYRIA)	86
	HEREDITARY COPROPORPHYRIA	86
	HEMOGLOBIN CATABOLISM	87
	Bilirubin Formation and Metabolism	90
	RED CELL LIFESPAN AND SURVIVAL	91
	Measurement of Red Cell Survival	93
3. The Anemias	Generic Signs and Symptoms of Anemia	111
	Variable or Inconstant Signs and Symptoms of Anemia	112
	Classification of Anemias	113
4. Aplastic Anemias	ETIOLOGY AND PATHOPHYSIOLOGY	115
	INCIDENCE, PREVALENCE, AND AGE OF ONSET	116
	IDIOPATHIC APLASTIC ANEMIA	117
	SECONDARY APLASTIC ANEMIAS	117
	Chemicals Causing Dose-Dependent Toxicity to Marrow Cells	117
	BENZENE	117
	ARSENIC	121
	ALCOHOL (ETHANOL)	121
	Drugs Causing Idiosyncratic Injury to Marrow Cells	123
	CHLORAMPHENICOL	123
	Ionizing Radiation	125
	Infections	127
	ACUTE APLASTIC CRISES (ACUTE ERYTHROBLASTOPENIA)	127
	Human Parvovirus Causes Most Aplastic Crises Occurring in Hemolytic Anemias	127
	VIRAL HEPATITIS	128
	Metabolic Derangements	129
	PATHOGENESIS OF APLASTIC ANEMIA	130
	Immunologic Mechanisms: Effects of Immunosuppression	130
	HEREDITARY (CONSTITUTIONAL) APLASTIC ANEMIAS	130
	FANCONI'S ANEMIA	130
	DYSKERATOSIS CONGENITA	131
	BLOOM'S SYNDROME	131
	"PURE" RED CELL APLASIA	131
	Acquired Pure Red Cell Aplasia	132
	Hereditary Pure Red Cell Aplasia	133
	Congenital Dyserythropoietic Anemias (CDAs)	133
	ANEMIA OF CHRONIC RENAL FAILURE	135
	BONE MARROW TRANSPLANTATION IN APLASTIC ANEMIA	136
	SYNGENEIC MARROW TRANSPLANTATION	137
	ALLOGENEIC MARROW TRANSPLANTATION	137
	GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH MARROW TRANSPLANTS	138
	INFILTRATIVE MYELOPATHIES (MYELOPHTHISIC ANEMIAS, LEUKOERYTHROBLASTIC ANEMIAS)	139
	Leukemias and Lymphomas	140
	Metastatic Carcinoma	140
	Disseminated Tuberculosis	141


5. Megaloblastic Anemias 153

- HYPERSEGMENTATION AND MACROOVALOCYTES 153
- THE MARROW IN MEGALOBlastic ANEMIAS 154
- Tests for Differentiating Megaloblastic Anemias 156
- VITAMIN B₁₂ DEFICIENCY 158
 - Dietary Deficiency of Vitamin B₁₂ 158
 - Deficiency of Gastric Intrinsic Factor: Pernicious Anemia 158
 - EPITHELIAL ATROPHY: THE GASTROINTESTINAL LESIONS 162
 - MEGALOBlastic ANEMIA OF PA 163
 - NEUROLOGIC ABNORMALITIES IN PA 163
 - THERAPY OF PA 165
 - VARIANT FORMS OF PA: CONGENITAL AND JUVENILE 166
- Gastrectomy 166
- Intestinal Malabsorption of Vitamin B₁₂ 166
 - COMPETITIVE PARASITES: FISH TAPEWORM DISEASE 167
 - BACTERIAL OVERGROWTH IN THE SMALL INTESTINE 167
- FOLATE DEFICIENCY 168
 - Dietary Deficiency 168
 - Impaired Absorption 169
 - Ingestion of Anticonvulsants or Other Drugs 170
 - Increased Folate Requirements 170
 - PREGNANCY AND THE MEGALOBlastic ANEMIA OF PREGNANCY 170
 - HEMOLYTIC ANEMIAS AND OTHER HYPERPROLIFERATIVE DISORDERS 171
 - Drug-Induced Suppression of DNA Synthesis 171
- INBORN ERRORS LEADING TO MEGALOBlastic ANEMIA 173

6. The Hypochromic Anemias and Other Disorders of Iron Metabolism 181

- IRON DEFICIENCY ANEMIA 181
 - Blood and Marrow Morphology 181
 - Assessment of Iron Stores 182
 - Clinical Manifestations of Iron Deficiency 185
 - ANEMIA 185
 - Behavioral Effects of Iron Deficiency 185
 - EPITHELIAL MANIFESTATIONS 186
 - Decreased Intake of Iron 188
 - MALABSORPTION OF IRON 188
 - Blood Loss 189
 - Impaired Iron Metabolism 190
 - Management of Iron Deficiency 190
 - Acute Iron Poisoning 191
- ANEMIA OF CHRONIC DISORDERS (ACD) 192
 - Tests for Differentiating ACD from Other Hypochromic Disorders 193
- SIDEROBLASTIC ANEMIAS 194
 - Hereditary Sideroblastic Anemias 195
 - Acquired Sideroblastic Anemias 196
 - IDIOPATHIC SIDEROBLASTIC ANEMIA (ISA) 196
 - DRUG-INDUCED SIDEROBLASTIC ANEMIAS 197
 - CHRONIC LEAD POISONING 198
 - THE ANEMIA OF LEAD POISONING 200
- CHRONIC IRON OVERLOAD 201
 - Idiopathic Hereditary Hemochromatosis 201
 - Differentiation of Hemochromatosis from Other Kinds of Iron Overload 204
 - MANAGEMENT 204
 - Erythropoietic Hemochromatosis 204
 - Iron Overload Secondary to Liver Disease 205
 - Increased Intake of Dietary Iron 206
 - AFRICAN SIDEROSIS 206
 - Parenteral Iron Overloading 206
 - CHELATION THERAPY 207
- THE THALASSEMIAS 207
 - Normal Globin Genes and Their Expression 207
 - α -Thalassemia (α -Thal) 208
 - α -Thal Minor (Heterozygous α -Thal-1 or Homozygous α -Thal-2) 209
 - Hemoglobin H Disease 210
 - Hydrops Fetalis with Hb Bart's 212
 - GENETIC AND MOLECULAR FEATURES OF THE β -THALASSEMIAS 212
 - β^+ -Thal 212
 - β^0 -Thal 213
 - $\delta\beta$ -Thal 213
 - $\gamma\delta\beta$ -Thal 213
 - Hereditary Persistence of Fetal Hemoglobin (HPFH) 214

	β-Thalassemic Syndromes 214
	THALASSEMIA MAJOR (HOMOZYGOUS β -THALASSEMIA; COOLEY'S ANEMIA) 214
	PRENATAL DIAGNOSIS OF β -THAL MAJOR 219
	β -THAL INTERMEDIA 220
	β -THAL MINOR 220
	β -THAL MINIMA 222
	Interactions of Thalassemias with Globin Structural Variants 222
7. Hemolytic Anemias Caused by Primary Defects of Red Cell Membranes 237	
	HEREDITARY SPHEROCYTOSIS 237
	MILD HS 237
	"TYPICAL" HS 238
	SEVERE HS 238
	Hematologic Findings in HS 238
	Pathophysiology 241
	THE MEMBRANE LESION IN HS 242
	THE ROLE OF THE SPLEEN IN HS 242
	Treatment 243
	HEREDITARY ELLIPTOCYTOSIS 243
	Hematologic Findings in HE 245
	Pathophysiology of HE 245
	Treatment 246
	Hereditary Pyropoikilocytosis (HPP) 246
	STOMATOCYTOSIS AND RELATED DISORDERS 247
	ACANTHOCYTOSIS 249
	Abetalipoproteinemia 249
	Spur Cell Hemolytic Anemia 250
	Other Causes of Acanthocytosis 251
	ANOREXIA NERVOSA, MALNUTRITION, MYXEDEMA 252
	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 252
	THE NATURE OF THE MEMBRANE DEFECT 252
	PNH IS A CLONAL MYELOYDYSPLASTIC DISORDER 253
	Description 254
	Hematologic Findings 256
	Management 256
	Marrow Transplantation 257
8. Secondary Defects of the Red Cell Membrane 265	
	MACROANGIOPATHIC HEMOLYTIC ANEMIAS 265
	MICROANGIOPATHIC HEMOLYTIC ANEMIA 266
	Disseminated Intravascular Coagulation 268
	Malignant Hypertension 269
	Disseminated Carcinoma 269
	Thrombotic Thrombocytopenic Purpura 269
	Hemolytic Uremic Syndrome 271
	OTHER PHYSICAL CAUSES OF HEMOLYSIS 272
	March (Exertional) Hemoglobinuria 273
	Burns 273
	HEMOLYSIS CAUSED BY MEMBRANE LYSINS 274
	Toxins and Venoms 274
9. Immunohemolytic Anemias 281	
	Pathophysiology of Immune Hemolysis 281
	RED CELL DESTRUCTION BY IgM ANTIBODIES 281
	Complement-Mediated Hemolysis 281
	RED CELL DESTRUCTION BY IgG ANTIBODIES 284
	Fc Receptor-Mediated Immune Hemolysis 284
	THE COOMBS TEST 288
	HEMOLYTIC TRANSFUSION REACTIONS 290
	Nonhemolytic Transfusion Reactions 292
	ISOIMMUNE HEMOLYTIC DISEASE OF NEWBORNS 293
	Rh Hemolytic Disease of the Newborn 293
	PRENATAL MANAGEMENT 294
	POSTNATAL MANAGEMENT 295
	Hemolytic Disease of the Newborn Caused by ABO Incompatibility 296
	AUTOIMMUNE HEMOLYTIC ANEMIAS 297
	Immunohemolytic Anemias Caused by Cold-Active Antibodies 297
	Cold Agglutinin Disease 298
	Paroxysmal Cold Hemoglobinuria 300
	Immunohemolytic Anemias Caused by Warm-Active Antibodies 300



HEMATOLOGIC FINDINGS 301
 Serologic Findings 303
 MANAGEMENT 304
 Corticosteroids 304
 High-Dose Intravenous IgG 305
 Splenectomy 306

Drug-Induced Immuno-hemolytic Anemias 306

HAPTEN-CELL MECHANISM OF DRUG-INDUCED HEMOLYTIC ANEMIA (PENICILLIN MODEL) 306
 IMMUNE COMPLEX MECHANISM OF DRUG-INDUCED HEMOLYTIC ANEMIA (STIBOPHEN MODEL) 307
 DRUG-INDUCED HEMOLYTIC ANEMIA: METHYLDOPA TYPE 308
AHA Secondary to Lymphoproliferative Disorders 309
AHA Secondary to Systemic Autoimmune Diseases 309

10. Hemolytic Anemias Caused by Infection of Red Cells 319

MALARIA 319

INFECTION OF RED CELLS BY PLASMODIA: RECEPTOR-MEDIATED ENDOCYTOSIS 319
 EPIDEMIOLOGY 320
 Tertian Malaria (*P. vivax* or *P. ovale*) 321
 Quartan Malaria (*P. malariae*) 321
 Falciparum Malaria (*P. falciparum*) 321
 RESISTANCE TO MALARIA 321

Hematologic Findings 322

SPLENOMEGALY AND TROPICAL SPLENOMEGALY SYNDROME 324

Management 325

CHEMOTHERAPY OF MALARIA 325
 IMMUNOPROPHYLAXIS (MALARIA "VACCINATION") 326

BABESIOSIS 327

Hematologic Findings 327

Treatment 328

OTHER PROTOZOAN INFECTIONS 328

Visceral Leishmaniasis (Kala-Azar) 328

HEMATOLOGIC FINDINGS 328
 TREATMENT 329

BARTONELLOSIS (CARRIÓN'S DISEASE) 330

HEMATOLOGIC FINDINGS 330
 TREATMENT 331

11. Heinz Body Hemolytic Anemias 335

PATHOPHYSIOLOGY OF OXIDATIVE HEMOLYSIS 335

The Pathologic Effects of Heinz Bodies 336

The Properties of Drugs That Cause Heinz Body Anemias 337

G6PD DEFICIENCY 338

G6PD AND ITS VARIANTS 338

Congenital Nonspherocytic Hemolytic Anemia (CNSHA) 339

Acute Hemolytic Anemia Induced by Oxidant Drugs 339

Favism 341

PATHOPHYSIOLOGY 341

HEMATOLOGIC FINDINGS 342

Other Enzyme Deficiencies Affecting HMP Shunt Activity 342

DIAGNOSIS AND SCREENING 343

G6PD DEFICIENCY IN NONERYTHROID CELLS 344

MANAGEMENT 345

12. Hemolytic Anemias Caused by Genetic Deficiencies in Glycolytic Enzymes 351

PYRUVATE KINASE DEFICIENCY 351

ALLOSTERIC REGULATION OF PK 351

PK DEFICIENCY IS USUALLY CAUSED BY DYSFUNCTIONAL MUTANT GENES 351

Hematologic Findings 352

Management 353

HEMOLYTIC ANEMIAS CAUSED BY OTHER DERANGEMENTS OF THE EMBDEN-MEYERHOF PATHWAY 353

Hexokinase (HK) Deficiency 353

Glucosephosphate Isomerase (GPI) Deficiency 354

Phosphofructokinase Deficiency 354

Triosephosphate Isomerase Deficiency 355

Phosphoglycerate Kinase (PGK) Deficiency 355

Other Glycolytic Enzymopathies 355

ABNORMALITIES OF NUCLEOTIDE METABOLISM 355

Pyrimidine Nucleotidase Deficiency 356

13. Abnormal Hemoglobins and Hemoglobinopathies 361

Genetic Mechanisms 361

- SINGLE BASE SUBSTITUTIONS 361
- ELONGATED SUBUNITS 362
- SHORTENED SUBUNITS 362
- FUSION SUBUNITS 362

Common Hb Variants and Their Detection 363

UNSTABLE HEMOGLOBIN DISEASE 363

- MECHANISM OF HEMOLYSIS 366

Hematologic Findings 367

HEMOGLOBIN S AND THE SICKLE CELL SYNDROMES 368

Pathophysiology 369

- POLYMERIZATION OF DEOXYHb S 369
- RED CELL SICKLING 371
- Irreversibly Sickled Cells 372

SICKLE CELL TRAIT 372

SICKLE CELL ANEMIA 373

Painful Crises 375

Bone and Joint Crises 376

Abdominal Crises 377

Neurologic Damage 377

Hepatic Crises and Hepatobiliary Damage 378

Genitourinary Complications 378

Pulmonary Manifestations 381

- CARDIOVASCULAR DAMAGE 381

Impaired Growth and Development 382

Hematologic Crises 382

Diagnosis 382

- MODULATION OF SICKLE CELL ANEMIA BY α GENE DELETIONS 383
- Hb S-HPFH 383
- HEMOGLOBIN SC DISEASE 385
- OTHER DOUBLY HETEROZYGOUS SICKLING DISORDERS 386
- Hb S- β -THALASSEMIA 386

Treatment of Sickle Cell Anemia 387

- MANIPULATION OF HEMOGLOBIN COMPOSITION 388
- MARROW TRANSPLANTATION 388
- ANTENATAL DIAGNOSIS 389

HEMOGLOBIN C DISORDERS 389

Hemoglobin C Trait (Hb AC) 389

Hemoglobin C Disease (Hb CC) 389

- HEMOGLOBIN C-THALASSEMIA 390

HEMOGLOBIN D DISORDERS 390

HEMOGLOBIN E DISORDERS 390

HEMOGLOBINOPATHIES WITH ABNORMAL OXYGEN BINDING 392

Hemoglobinopathies Producing Erythrocytosis 392

Hb Variants with Low O₂ Affinity 394

HEMOGLOBIN M DISORDERS 395

14. The Spleen and Hypersplenism 407

STRUCTURE AND FUNCTIONS OF THE SPLEEN 407

- THE WHITE PULP AND RECIRCULATION OF LYMPHOCYTES 407
- THE RED PULP 409
 - The Sinus Compartment 409
 - Splenic Cords 410

Hemodynamic Features of Normal Versus Enlarged Spleens 410

- RED CELL POOLING 411
 - Dilutional Anemia in Splenomegalic Disorders 412
 - Massive Splenomegaly and Portal Hypertension 413
- PLATELET POOLING 413

Specialized Functions of the Spleen 415

- SPLEEN POOLING VERSUS FILTRATION 417
- IMMUNOLOGIC ROLE OF THE SPLEEN 417
- THE POSTSPLENECTOMY AND ASPLENIC STATES 418

SPLENOMEGALIC DISORDERS 419

- RADIONUCLIDE IMAGING 419
 - Ultrasonic Imaging 420
 - X-Ray Computed Tomography (CT Scans) 420
 - Magnetic Resonance Imaging 420

Pathogenesis of Splenomegalic Disorders 421

- INFLAMMATORY SPLENOMEGALY 421
- TRAUMATIC RUPTURE OF THE SPLEEN IN SPLENOMEGALIC DISORDERS 421
- CHRONIC CONGESTIVE SPLENOMEGALY 423

	Splenic Hyperplasia	424
	Infiltrative Splenomegaly	424
	Cysts and Solid Tumors	424
	SPLENECTOMY	425
	Splenic Salvage	425
	Complications of Surgery	426
	Splenosis	426
15. Polycythemia:		
Erythrocytosis	433	
	POLYCYTHEMIA AT HIGH ALTITUDE	433
	Pathophysiology	433
	Acute Mountain Sickness: Hypoxic Cerebral Edema	434
	Chronic Mountain Sickness (Monge's Disease)	434
	POLYCYTHEMIA SECONDARY TO PULMONARY DISEASE	435
	POLYCYTHEMIA SECONDARY TO VASCULAR ANOMALIES	435
	POLYCYTHEMIA SECONDARY TO HYPOVENTILATION	436
	POLYCYTHEMIA CAUSED BY DEFECTIVE O₂ TRANSPORT	436
	HEREDITARY METHEMOGLOBINEMIA	436
	POLYCYTHEMIA SECONDARY TO INAPPROPRIATE EP PRODUCTION	437
	Hereditary Erythrocytosis	438
16. Granulocytes	441	
	Committed Stem Cells (CFU-GM, CFU-M, and CFU-G)	441
	GRANULOCYTE AND MACROPHAGE COLONY STIMULATING FACTORS	442
	MORPHOLOGY OF DIFFERENTIATING GRANULOCYTES	444
	Neutrophils	444
	Eosinophils	446
	Basophils	448
	Mast Cells	449
	NEUTROPHIL KINETICS	450
	NEUTROPHIL FUNCTION	451
	The Sensory Limb of Neutrophil Reaction	452
	The Motor Limb of Neutrophil Reaction	454
	Motile Cytoplasmic Responses of Neutrophils	456
	Neutrophil O ₂ Metabolism and Antimicrobial Activity	458
	The Price of Neutrophil Defense: Inflammation	459
	NEUTROPHILIA OF ACUTE INFECTION OR INFLAMMATION	460
	MORPHOLOGIC CHANGES IN NEUTROPHILS DURING INFECTION	460
	NEUTROPENIA DURING INFECTION AND INFLAMMATION	462
	Morbid Neutropenia of Overwhelming Infection	462
	LEUKEMOID REACTIONS	462
17. Monocytes and Macrophages	473	
	Morphology and Cytokinetics	473
	Monocyte-Macrophage Transformation	477
	THE SENSORY LIMB OF MACROPHAGE REACTION	478
	THE MOTOR LIMB OF MACROPHAGE REACTION	479
	PHAGOCYTOSIS	480
	Role of Mononuclear Phagocytes in Immunity	482
	ANTIGEN UPTAKE AND PRESENTATION BY MACROPHAGES	482
	Antigen Recognition by T Cells: The T Cell Antigen-MHC Receptor	483
	The IL-2-Dependent Autocrine Pathway of Macrophage-Educated T Cells	483
	Mononuclear Phagocyte Responses to Infection and Inflammation	483
	GRANULOMA FORMATION	485
	OSTEOCLASTS	485
	OTHER TISSUE MACROPHAGES	486
	Langerhans Cells and Other Antigen-Presenting Specialized Macrophages	486
	Common Causes of Monocytosis	487
	MONOCYTOPENIA	488
	LIPID STORAGE DISEASES	489
	GAUCHER'S DISEASE: GLUCOSYLCERAMIDE LIPIDOSIS	489
	NIEMANN-PICK DISEASE: SPHINGOMYELIN LIPIDOSES	490
	SEA BLUE HISTIOCYTES	491
	HISTIOCYTOSES	491
	EOSINOPHILIC GRANULOMA OF BONE	493
	PROLIFERATIVE HISTIOCYTIC DISEASE WITH WELL DIFFERENTIATED CELLS: HAND-SCHÜLLER-CHRISTIAN DISEASE	494
	HISTIOCYTIC DISEASES WITH MODERATE CELLULAR DIFFERENTIATION: LETTERER-SIWE DISEASE	495
	Malignant Histiocytosis (Histiocytic Medullary Reticulosis)	496
	Fabry's Disease	497

18. Lymphocytes and Plasma Cells 505

B CELLS 506

The Structural Basis of Antibody Diversity 506

B CELL IMMUNOGLOBULIN GENES ARE CHARACTERIZED BY DNA REARRANGEMENTS 506

Mechanisms of Clonal Diversity 506

B CELL MATURATION AND REPLICATION 507

Kinetics and Migratory Patterns 508

B Cell Activation by Antigen 510

MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) AND HLA ANTIGENS 510

Two Classes of MHC-Encoded Antigens 511

MHC RESTRICTION IN T-DEPENDENT B CELL ACTIVATION 512

B CELL REPLICATION AND MATURATION FACTORS 512

TERMINAL MATURATION STAGES: B CELLS, IMMUNOBLASTS, AND PLASMA CELLS 513

Plasma Cells 514

IDIOTYPE-ANTIIDIOTYPE INTERACTIONS 515

Locomotion, Migration, and Receptor Regulation 516

LYMPHOCYTE CYTOSKELETON AND ITS CONTROL BY SURFACE RECEPTORS 520

Receptor Switching and Affinity Maturation 522

T CELLS. THE T CELL NETWORK 522

Cellular Immunity 523

Thymocyte Differentiation 523

The T Cell Antigen Receptor (TcR) 525

Ti Gene Analysis of T Cell Neoplasms 526

Characterization of Major T Cell Subsets: T4 and T8 527

CYTOTOXIC T CELLS 527

HELPER AND SUPPRESSOR T CELLS 529

Lymphokines 530

AFFERENT LYMPHOKINES 530

Interleukin 1 (IL-1) and T Cell Replacing Factor (TRF) 530

Interleukin 2 (IL-2) and the IL-2 Receptor 530

EFFERENT LYMPHOKINES 532

Migration Inhibitory Factors 532

Macrophage Chemotactic Factor (MCF) 532

Macrophage-Activating Factor (MAF) 532

Lymphotoxin (LT) 532

Large Granular Lymphocytes (LGLs) Are Natural Killer Cells (NK Cells) 533

MORPHOLOGY 533

TARGET CELL LYSIS. NK CELLS ARE PROFESSIONAL KILLERS 535

Regulation of NK Activity by Interferons 535

THE ROLE OF NK CELLS IN IMMUNE SURVEILLANCE 536

NK Cell Regulation of Hematopoiesis 537

INFECTIOUS MONONUCLEOSIS 537

EPIDEMIOLOGY 537

PATHOGENESIS 538

Description 538

IMMUNOLOGY OF INFECTIOUS MONONUCLEOSIS 542

IMMUNODEFICIENCY STATES AND EBV INFECTION 543

X-Linked Lymphoproliferative Syndrome 543

Burkitt's Lymphoma 544

HETEROPHIL-NEGATIVE MONONUCLEOSIS SYNDROMES 544

Cytomegalovirus Mononucleosis 544

IMMUNODEFICIENCY STATES 545

X-LINKED AGAMMAGLOBULINEMIA 545

COMMON VARIABLE IMMUNODEFICIENCY SYNDROMES 546

SEVERE COMBINED IMMUNODEFICIENCY (SCID) 546

HEREDITARY ATAXIA TELANGIECTASIA 547

WISKOTT-ALDRICH SYNDROME 547

CONGENITAL THYMIC APLASIA (DI GEORGE'S SYNDROME) 547

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 548

ETIOLOGY AND EPIDEMIOLOGY 548

Human Immunodeficiency Virus 548

HTLV-III Is Tropic for T4 Helper Cells and for Macrophages 548

AIDS Virus Productivity and Trans-Activation 549

Serologic Responses and Screening Tests 550

Hematologic Abnormalities 551

Lymphomas 551

CNS Damage 551

Infection Control Guidelines 551

Miscellaneous Lymphocyte Abnormalities 552

ACUTE INFECTIOUS LYMPHOCYTOSIS 552

BORDETELLA PERTUSSIS INFECTION 552

TOXOPLASMOSIS AND OTHER CHRONIC INFECTIONS 553

DRUG-INDUCED HYPERSENSITIVITY REACTIONS 554

SERUM SICKNESS 554

19. Leukocyte Anomalies 571

- HEREDITARY STEM CELL DEFICIENCIES 571**
 Cyclic Hematopoiesis (Cyclic Neutropenia) 571
 Congenital Agranulocytosis (Kostmann's Disease) 571
 Neutropenia and Pancreatic Insufficiency (Shwachman Syndrome) 572
 Immune Neutropenias 572
 DRUG-INDUCED AGRANULOCYTOSIS 573
Pelger-Huët Anomaly 574
 ACQUIRED OR PSEUDO PELGER-HUET ANOMALY 574
May-Hegglin Anomaly 575
 Leukocyte Inclusion Bodies in Mucopolysaccharidoses: The Alder-Reilly Anomaly 576
Jordans Anomaly 577
 Hereditary Hypersegmentation of Neutrophils 577
 Hereditary Giant Neutrophilia 577
Chédiak-Higashi Syndrome 577
 PATHOGENESIS 577
 DESCRIPTION 578
 MANAGEMENT 579
DEFECTS IN MICROBICIDAL ACTIVITY 580
Chronic Granulomatous Disease 580
 PATHOGENESIS AND GENETICS 580
 Description 580
 COURSE AND MANAGEMENT 582
Myeloperoxidase Deficiency 582
Other Functional Anomalies of Neutrophils 582

20. Hematopoietic Malignancies 589

- ONCOGENES AND MULTISTEP CARCINOGENESIS 589**
Retrovirus-Associated Oncogenesis 589
 CELLULAR EXPRESSION OF V-ONCOGENES: THE C-ONCOGENES 591
Mechanism of Activation of Oncogenes 592
 POINT MUTATION 592
 Oncogenes, Growth Factors, and Growth Factor Receptors 593
Chromosomal Rearrangements 593
 The Burkitt Lymphoma Model 596
 The 9;22 Translocation of Ph⁺ Leukemias 597
 CHROMOSOMAL REARRANGEMENTS IN ACUTE MYELOGENOUS LEUKEMIAS 598
 FRAGILE SITES 599
Gene Deletions. The -5, 5q-, -7, and 7q- Syndromes 600
 Pathogenesis of the 5q Deletions 602
 SECONDARY LEUKEMIAS 602
 LEUKEMIA SECONDARY TO IONIZING RADIATION 603
 Low-Dose Exposure to Penetrating Radiation 603
 Medical Overexposure 603
 Japanese Survivors of Atomic Bombs 604
Amplification and Promotion 605
HUMAN T CELL LYMPHOTROPIC RETROVIRUSES (HTLV) 607
 HUMAN T CELL LEUKEMIA-LYMPHOMA VIRUS (HTLV-I) 607
 Characteristics of the Virus 608
 The x Gene Product, pX, Is Essential for HTLV Replication 608
Description of HTLV-I-Induced Lymphoproliferative Syndromes 609
 Lymphadenopathy 610
 Cutaneous T Cell Infiltrations 610
 Hypercalcemia and Osteolytic Lesions 611
 HEMATOLOGIC FINDINGS 611
 MANAGEMENT 612
MYELOYDYSPLASTIC SYNDROMES 612
 Description 612
 CHROMOSOMAL ABNORMALITIES 616
Hematologic Findings 617
 REFRACTORY ANEMIA 617
 REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS 618
 REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB) 618
 Chronic Myelomonocytic Leukemia (CMML) 619
 RAEB IN TRANSFORMATION 619
Management 619

21. Acute Myelogenous Leukemia 629

- Classification of the Leukemias 630**
The FAB Classification Is Provisional 630
Incidence 631
Clinical Findings 633

Myeloblastomas	634
HYPERLEUKOCYTIC SYNDROMES	636
HEMATOLOGIC FINDINGS	637
Auer Rods and Phi Bodies	638
AML Without Maturation	639
AML with Maturation	639
Acute Promyelocytic Leukemia (APL)	640
APL PATIENTS DEVELOP DIC AND BLEEDING	640
Acute Myelomonocytic Leukemia	641
Acute Monocytic Leukemia	643
AMoL SUBTYPES: M5 _A AND M5 _B	644
Erythroleukemia	647
Megakaryoblastic Leukemia	648
Mast Cell Leukemia	648
URTICARIA PIGMENTOSA, SYSTEMIC MASTOCYTOSIS, AND MAST CELL LEUKEMIA	649
THERAPY OF AML	649
Chemotherapy	649
REMISSION INDUCTION	651
Failure of Remission Induction	653
Partial Remission	653
CONSOLIDATION AND MAINTENANCE THERAPY	654
Immunotherapy	655
Chemical Induction of Differentiation	655
Marrow Transplantation	655
HLA ANTIGENS AND TISSUE COMPATIBILITY	655
Selection of Donors	657
PRETRANSPLANT CONDITIONING REGIMENS	657
Marrow Transplantation Given During First Remission	658
Relapse Often Represents Leukemic Transformation of Donor Cells	658
Autologous Marrow Transplantation: Selective Purging of Leukemic Cells	659
PREVENTION AND TREATMENT OF GVHD	659
Acute GVHD	659
Chronic GVHD	659
PREVENTION OF GVHD	660
Immunosuppressive Agents	660
T Cell Purging by Immunotoxins	660
Treatment of Established GVHD	661
OTHER COMPLICATIONS	661
Posttransplant Immunodeficiency	661
Infectious Complications	661

22. Chronic Myeloproliferative Syndromes 671

CHRONIC MYELOGENOUS LEUKEMIA	671
Pathogenesis and Pathophysiology	671
Ph ¹ CHROMOSOME RESULTS FROM A t(9;22) TRANSLOCATION	671
c-abl : bcr Gene Fusion Leads to Production of a Novel Protein Growth Factor	672
Most Patients with Atypical CML Have a Clonal Myelodysplastic Syndrome	673
G6PD ISOZYME STUDIES	673
CLONAL EVOLUTION: BLAST CRISIS	675
Blast Crises Are Heterogeneous	675
Description	676
CLINICAL FEATURES OF THE CHRONIC PHASE	676
Secondary Myelofibrosis	677
Leukostasis	677
CNS Involvement	677
Hypercalcemia and Osteolytic Bone Lesions	679
Bleeding and Thrombosis	679
Basophilia with Hyperhistaminemia	679
Hematologic Findings	679
CHRONIC PHASE	680
Leukocyte Alkaline Phosphatase	681
ACCELERATED PHASE (ACUTE TRANSFORMATION)	682
BLAST CRISIS	682
Hematologic Changes During Myeloid Blast Crisis	683
Lymphoid Blast Crisis	683
ATYPICAL CML	684
Course and Prognosis	684
Treatment	685
CONVENTIONAL CHEMOTHERAPY FOR CHRONIC PHASE CML	685
Acute Cytorreduction. Leukapheresis. Splenic Irradiation	687
Total Body Irradiation	688
Maturation Induction: A Futuristic Approach	688
MANAGEMENT OF THE ACCELERATED PHASE	688

MANAGEMENT OF BLAST CRISES	688
Myeloid Blast Crisis	688
Lymphoid Blast Crisis	689
Marrow Transplantation	689
AUTOLOGOUS TRANSPLANTS	689
SYNGENEIC MARROW TRANSPLANTS	689
ALLOGENEIC MARROW TRANSPLANTATION	689
Leukemic Transformation of Engrafted Marrow	690
IDIOPATHIC MYELOFIBROSIS	690
Pathogenesis and Pathophysiology	691
Regulation of Marrow Collagen	691
PDGF and the C-sis Oncogene Product	692
Description	692
EXTRAMEDULLARY HEMATOPOIESIS	693
OSTEOSCLEROSIS AND OTHER SKELETAL DEFECTS	695
Hematologic Findings	695
MORPHOLOGY	695
Anemia	696
White Counts	696
Platelet Levels and Hemostasis	697
Marrow Findings	697
Differential Diagnosis	698
Treatment	699
SPLENECTOMY REDUX	700
Prognosis	700
POLYCYTHEMIA VERA	701
Pathophysiology	701
ERYTHROPOIETIN LEVELS	701
ERYTHROID COLONY GROWTH IN PV	702
Description	703
CIRCULATORY DISTURBANCES OF THE CNS	703
CARDIOVASCULAR AND RESPIRATORY PROBLEMS IN PV	704
SPLENOMEGALY	704
Hematologic and Laboratory Findings	705
POSTPOLYCYTHEMIC MYELOFIBROSIS	706
AML IN PV	706
Treatment	707
PHLEBOTOMY	708
³² P	709
HYDROXYUREA	709
THROMBOCYTHEMIA	709
Pathophysiology	709
PLATELET ABNORMALITIES	711
Description	711
BLEEDING	711
THROMBOSIS	711
Hematologic Findings	711
LEUKEMIC METAMORPHOSIS	712
Treatment	712
Antiaggregating Agents in Controlling Thrombotic Complications	713
INCIDENCE, CLASSIFICATION, AND PATHOPHYSIOLOGY	727
Immunologic Classification	727
T CELL ALL	727
MOST NON-T CELL ALLs ARE OF B CELL LINEAGE	728
Morphologic Classification	728
Cytogenetics in ALL	730
DESCRIPTION	733
BONE AND JOINT INVOLVEMENT	733
Extramedullary ALL	733
CNS LEUKEMIA	733
TESTICULAR INVOLVEMENT	735
HEMATOLOGIC FINDINGS	735
Lymphoblast Morphology	736
HISTOCHEMICAL PROFILE	736
RED COUNTS AND PLATELET LEVELS	737
Marrow	738
THERAPY	739
Combination Chemotherapy of ALL	739
CENTRAL NERVOUS SYSTEM THERAPY	741
Toxicity of CNS Therapy	742

23. Acute Lymphatic Leukemia 727

50% B-cell ALL

platelet profile

24. Chronic Lymphatic Leukemia 751

THERAPY OF TESTICULAR RELAPSE 742

2-DEOXYCOFORMYCIN 743

Marrow Transplantation 743

Transplantation During First Remission 743

Autologous Marrow Transplantation 744

INCIDENCE AND EPIDEMIOLOGY 751

PATHOPHYSIOLOGY 751

CLL Is a Monoclonal Disease 751

CHROMOSOME ABNORMALITIES 753

Hypogammaglobulinemia Is Caused by Unbalanced Immunoglobulin Chain

Synthesis 755

Cytokinetics 755

DESCRIPTION 755

Systemic Manifestations 756

Local Manifestations 756

SKIN 757

LYMPHADENOPATHY AND SPLENOMEGALY 757

GASTROINTESTINAL TRACT 757

LUNGS 757

NEUROLOGIC COMPLICATIONS 758

Monoclonal Immunoglobulin Secretion 758

SECOND MALIGNANCIES IN CLL 758

Hematologic Findings 758

CLL LYMPHOCYTES 758

ANEMIA, THROMBOCYTOPENIA, AND NEUTROPENIA 759

Pure Red Cell Aplasia in B-CLL 760

Autoimmune Hemolytic Anemia 761

MARROW FINDINGS 761

Richter's Syndrome 762

T Cell CLL 764

T4-CLL 764

T8-CLL (Chronic T Cell Lymphocytosis) Is an Indolent Clonal Disorder 766

TREATMENT 767

STAGING AND PROGNOSTIC CLASSIFICATION OF CLL 768

CORTICOSTEROIDS 768

ALKYLATING AGENTS 770

Ionizing Radiation 771

LOCAL IRRADIATION 771

Splenic Irradiation 771

Endolymphatic Radiotherapy 771

TOTAL BODY IRRADIATION 771

MARROW TRANSPLANTATION 772

25. Prolymphocytic and Hairy Cell Leukemias 779

PROLYMPHOCYTIC LEUKEMIA 779

Pathophysiology 779

CYTOGENETICS 780

Description 780

Hematologic Findings 781

Cytochemical Stains Distinguish B-PLL and T-PLL 781

BLOOD COUNTS AND MARROW FINDINGS 782

Prolymphocytoid Transformation of CLL 782

Therapy 783

TREATMENT OF T-PLL WITH DEOXYCOFORMYCIN 784

HAIRY CELL LEUKEMIA 785

Pathophysiology 786

HAIRY CELLS ARE PHENOTYPIC HYBRIDS 786

T Cell Variant 786

IMMUNOLOGIC FEATURES OF HAIRY CELLS: A REPRISÉ 787

Description 787

THE HAIRY CELL 787

SPLENOMEGALY 788

LYMPH NODES 788

PARAPROTEINEMIA 789

OSTEOLYTIC LESIONS 789

INVOLVEMENT OF NONHEMATOPOIETIC ORGANS 789

Hematologic Features 790

BLOOD FINDINGS 790

Monocyte Depletion 790

MARROW EXAMINATION 791

26. Multiple Myeloma and Other Differentiated B Cell Malignancies 801

- Treatment 792**
 - SPLENECTOMY IS THE PREFERRED THERAPY FOR HCL 793
 - 2'-Deoxycoformycin 793
 - Radiation Therapy 795
 - ALPHA-2-INTERFERON MAY SUPPLANT SPLENECTOMY AS INITIAL THERAPY 795
 - MARROW TRANSPLANTATION 795
- Secondary Complications 796**
 - INFECTIOUS COMPLICATIONS 796
 - SECOND MALIGNANCIES 796
- Incidence 801**
- PATHOPHYSIOLOGY 801**
 - Idiotypic Antigens 802
 - MM PATIENTS ARE DEFICIENT IN HUMORAL BUT NOT CELLULAR IMMUNITY 803
 - Monoclonal Ig Chain Synthesis Is Often Unbalanced or Deranged 804
- Chromosomal Abnormalities 804**
- Cytokinetics in MM 804**
- DESCRIPTION 806**
 - Skeletal Disease 807**
 - RADIOLOGIC CHANGES 807
 - HYPERCALCEMIA 808
 - Management of Hypercalcemic Complications of Myeloma 809
 - Monoclonal Protein Abnormalities 810**
 - LIGHT CHAIN DISEASE 810
 - IgG MYELOMA 811
 - IgA MYELOMA 811
 - IgD MYELOMA 812
 - IgE MYELOMA 813
 - IgM MYELOMA 813
 - BICLONAL GAMMOPATHIES 814
 - Variant Myeloma Products 814**
 - Ig HALF-MOLECULES 814
 - HEAVY CHAIN DISEASES 814
 - γ HCD 814
 - α HCD 815
 - μ HCD 816
 - NONSECRETORY MYELOMA 816
 - AMYLOIDOSIS AND MM 816
 - Clinical Features of AL Amyloidosis 818
 - BENIGN MONOCLONAL GAMMOPATHY 819
 - Premalignant BMG 820
 - Hypersusceptibility to Infection 820**
 - Neurologic Malfunctions 821**
 - SENSORIMOTOR POLYNEUROPATHY 822
 - Multifocal Leukoencephalopathy 822
 - Hyperviscosity Syndrome 822
 - Renal Disease 822**
 - MYELOMA CAST NEPHROPATHY (BENCE JONES NEPHROSIS) 823
 - GLOMERULAR LESIONS 823
 - Diffuse κ Chain Nephropathy 824
 - TREATMENT OF RENAL FAILURE 825
 - Solitary and Extraosseous Myelomas 826**
 - SOLITARY OSSEOUS MYELOMAS 827
 - EXTRAOSSEOUS MYELOMA 827
 - HEMATOLOGIC FINDINGS 828**
 - Blood 828**
 - Bone Marrow 829**
 - MYELOMA CELL MORPHOLOGY 829
 - Plasma Cell Leukemia 831**
 - MANAGEMENT 832**
 - Relief of Pain Is Essential to Maintaining Mobility 832**
 - Calcitonin Alleviates Skeletal Pain in MM 833
 - Stabilization of Skeletal Healing 833
 - Chemotherapy of MM 834**
 - ALKYLATING AGENTS 835
 - MULTIPLE DRUG COMBINATIONS 836
 - Irradiation 837**
 - MM and Therapy-Related Acute Myelogenous Leukemia 837**
 - WALDENSTRÖM'S MACROGLOBULINEMIA 838**
 - Description 838